Enhancing oral bioavailability of methylnaltrexone using an emulsion formulation

Letters in Drug Design and Discovery

Volumn 8, Issue 1, 2011, Pages 87-92

  Yu, Li Fang ^a   Lu, Wei Gen ^a   Xiang, Ping ^b   Wang, Li Li ^a   Li , Chen ^a   Chen, Ting Ting ^a   Gu, Michael Maojian ^c   Wang, Chong Zhi ^d   Yuan, Chun Su ^d  

^a Shanghai Institute of Pharmaceutical Industry   (China)

^b INSTITUTE OF FORENSIC SCIENCE   (China)

^c Shanghai JNJ PharmaTech   (China)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Emulsion; Formulation; LC MS MS; Liquid chromatography mass spectrometry; Methylnaltrexone; Oral bioavailability

Indexed keywords

17 METHYLNALTREXONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; EMULSION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 78650919028     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018011793663886     Document Type: Article

References (22)

1. Glare, P.; Lickiss J.N. Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J. Pain Symptom Manage., 1992, 7, 369-371.
2. Meier, D.E.; Morrison R.S.; Cassel C.K. Improving palliative care. Ann. Intern. Med., 1997, 127, 225-230.
3. Sykes, N.P. The use of oral naloxone in the management of opioid bowel dysfunction. In Handbook of Opioid Bowel Syndrome; New York: Haworth Medical Press, 2005, pp. 69-100.
4. Goldberg, L.I.; Merz H.; Stockhaus K. Quaternary derivatives of noroxymorphone which relieve intestinal immobility. A61K 41/485 Edition. U.S. Patent 78-928821, 4176186, Jul 28, 1978
5. Russell, J.; Bass P.; Goldberg L.I.; Schuster C.R.; Merz H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur. J. Pharmacol., 1982, 78, 255-261.
6. Yuan, C.S. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann. Pharmacother., 2007, 41, 984-993.
7. Yuan, C.S.; Foss J.F.; O'Connor M.; Osinski J.; Karrison T.; Moss J.; Roizen M.F. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA, 2000, 283, 367-372.
8. Yuan, C.S.; Foss J.F.; Osinski J.; Toledano A.; Roizen M.F.; Moss J. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin. Pharmacol. Ther., 1997, 61, 467-475.
9. Yuan, C.S.; Foss J.F.; O'Connor M.; Karrison T.; Osinski J.; Roizen M.F.; Moss J. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin. Pharmacol. Ther., 2000, 67, 398-404.
10. The U.S. Food and Drug Administration (FDA) website,http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2008/ucm116885.htm, (accessed Oct 8, 2009).
11. Bjerregaard, S.; Soderberg I.; Vermehren C.; Frokjaer S. Formulation and evaluation of release and swelling mechanism of a water-in-oil emulsion using factorial design. Int. J. Pharm., 1999, 193, 1-11.
12. Bjerregaard, S.; Pedersen H.; Vedstesen H.; Vermehren C.; Soderberg I.; Frokjaer S. Parenteral water/oil emulsions containing hydrophilic compounds with enhanced in vivo retention: formulation, rheological characterisation and study of in vivo fate using whole body gamma-scintigraphy. Int. J. Pharm., 2001, 215, 13-27.
13. Kim, C.; Cheng R.; Corrigall W.A.; Coen K.M. Assay for methylnaltrexone in rat brain regions and serum by highperformance liquid chromatography with coulometric electrochemical detection. Chromatographia, 1989, 28, 359-363.
14. Osinski, J.; Wang A.; Wu J.A.; Foss J.F.; Yuan C.S. Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 780, 251-259.
15. Eaimtrakarn, S.; Rama Prasad Y.V.; Ohno T.; Konishi T.; Yoshikawa Y.; Shibata N.; Takada K. Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats. J. Drug Target, 2002, 10, 255-260.
16. Koga, K.; Kawashima S.; Murakami M. In vitro and in situ evidence for the contribution of Labrasol and Gelucire 44/14 on transport of cephalexin and cefoperazone by rat intestine. Eur. J. Pharm. Biopharm., 2002, 54, 311-318.
17. Prasad, Y.V.; Puthli S.P.; Eaimtrakarn S.; Ishida M.; Yoshikawa Y.; Shibata N.; Takada K. Enhanced intestinal absorption of vancomycin with Labrasol and D-alpha-tocopheryl PEG 1000 succinate in rats. Int. J. Pharm., 2003, 250, 181-190.
18. Graf, A.; Rades T.; Hook S.M. Oral insulin delivery using nanoparticles based on microemulsions with different structuretypes: optimisation and in vivo evaluation. Eur. J. Pharm. Sci., 2009, 37, 53-61.
19. Djordjevic, L.; Primorac M.; Stupar M.; Krajisnik D. Characterization of caprylocaproyl macrogolglycerides based microemulsion drug delivery vehicles for an amphiphilic drug. Int. J. Pharm., 2004, 271, 11-19.
20. Porter, C.J.; Pouton C.W.; Cuine J.F.; Charman W.N. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev., 2008, 60, 673-691.
21. Yuan, C.S.; Wei G.; Foss J.F.; O'Connor M.; Karrison T.; Osinski J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J. Pharmacol. Exp. Ther., 2002, 300, 118-123.
22. Yuan, C.S.; Foss J.F.; Williams W.A.; Moss J. Development and use of methylnaltrexone, a peripherally acting opioid antagonist, to treat side effects related to opioid use. Drug Dev. Res., 2009, 70, 403-416